Intracameral amphotericin B may be an effective adjunctive treatment of fungal keratitis unresponsive to conventional antifungal therapy, although cataract may occur.

Hereditary lacrimal fistula is a rare developmental anomaly. We report three patients with congenital lacrimal fistulae in the same family. Only one of our cases had bilateral lacrimal fistula while two had unilateral lacrimal fistulae. No other systemic or ocular anomaly was found in the affected subjects. In the absence of significant symptoms, we did not feel the necessity of any treatment for these lacrimal fistulae. The presence of a lacrimal fistula is an indication for the search for a variety of systemic and ocular associations in affected patients.

The authors report a rare case of hemangiopericytoma-solitary fibrous tumor of the eyelid. A 35-year-old male presented with approximately 1-year history of a painless and slow growing mass on his right lower eyelid, which rapidly grew in size over the last few months. The size of the lesion and the location resulted in secondary mechanical ectropion at presentation. The tumor was excised and was found to be a "hemangiopericytoma-solitary fibrous tumor" based on both histopathological and immunohistochemical examinations. Immunohistochemically, the tumor was positive for CD34 and Vimentin but negative for S100 protein and smooth muscle actin. Although initial tumor removal was complete, the patient required a subsequent operation for his residual ectropion. Despite the lesion being large at presentation, surgical intervention resulted in good functional and cosmetic outcome.

We report the case of a 41-year-old female with bilateral orbital Rosai-Dorfman disease (RDD) and the result of corticosteroid therapy. The patient developed a swollen mass of bilateral upper and lower eye-lid over a six-month period. Diagnosis was based on the characteristic histopathologic features. She was treated with oral corticosteroids 60 mg/per day for ten days and the dose of corticostreoid was tapered every week. She is currently being treated with 10 mg/per day for 4 months. In general, the prognosis is good, with experiencing remission following a course of oral corticosteroids. There is no evidence that corticosteroids are beneficial in the treatment of RDD in the literature, but data regarding such treatment are sparse. A more formalized surveillance of these cases would help to define more clearly the natural history of the disease and the effects of various treatment modalities.